The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

The Chinese biotech will now pursue the further development of ASC30 in obesity for use as a maintenance and treatment ...

ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective ...

CVS Caremark is facing a lawsuit after being accused of pointing patients to use a weight loss drug called Wegovy and for ...

A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...

Benefits consultants Aon and WTW told the Wall Street Journal that employer health-coverage costs are set to surge about 9.5% ...

CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound ...

Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...

A new weight-loss drug targets four hormones for major results and fewer side effects. Discover what makes the tetra-agonist ...